Background. The human regulatory macrophage (Mreg) has emerged as a promising cell type for use as a cell-based adjunct immunosuppressive therapy in solid organ transplant recipients. In this brief report, dehydrogenase/reductase 9 (DHRS9) is identified as a robust marker of human Mregs. Methods. The cognate antigen of a mouse monoclonal antibody raised against human Mregs was identified as DHRS9 by immunoprecipitation and MALDI-MS sequencing. Expression of DHRS9 within a panel of monocyte-derived macrophages was investigated by quantitative PCR, immunoblotting and flow cytometry. Results. DHRS9 expression discriminated human Mregs from a panel of in vitro derived macrophages in other polarisation states. Likewise, DHRS9 expression distinguished Mregs from a variety of human monocyte-derived tolerogenic antigen-presenting cells in current development as cell-based immunotherapies, including Tol-DC, Rapa-DC, DC-10, and PGE 2 -induced myeloid-derived suppressor cells. A subpopulation of DHRS9-expressing human splenic macrophages was identified by immunohistochemistry. Expression of DHRS9 was acquired gradually during in vitro development of human Mregs from CD14 + monocytes and was further enhanced by IFN-γ treatment on day 6 of culture. Stimulating Mregs with 100 ng/mL lipopolysaccharide for 24 hours did not extinguish DHRS9 expression. Dhrs9 was not an informative marker of mouse Mregs. Conclusion. DHRS9 is a specific and stable marker of human Mregs.
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(Transplantation 2017;101: 2731-2738) S everal immunoregulatory cell-based products are presently being investigated as adjunct immunosuppressive agents in early-phase clinical trials in solid organ transplantation. 1 One particularly promising candidate cell type is the regulatory macrophage (Mreg). The human Mreg represents a unique state of macrophage polarisation, which is distinguished from other activation states by a constellation of cell-surface markers and potent T cell suppressor function. 2 Human Mregs suppress mitogen-stimulated Tcell proliferation in vitro through interferon-gamma (IFN-γ)-induced indoleamine 2,3-dioxygenase (IDO) activity, as well as contact-dependent deletion of activated T cells. 3 In addition, Mregs drive the development of activated induced regulatory T cells that, in turn, suppress the proliferation and activity of effector T cells (Riquelme-P et al, unpublished) . Human Mregs derive from CD14 + peripheral blood monocytes when cultured in the presence of macrophage colony-stimulating factor (M-CSF) and high concentrations of heat-inactivated human serum for more than 4 days before stimulation with IFN-γ. A proprietory good manufacturing practice (GMP)-compliant process for manufacturing a therapeutic product, known as Mreg_UKR, containing human Mregs has been established at a commercial pharmaceutical manufacturing facility in Germany. 4 Now, Mreg_UKR is being investigated in a Phase-I/II trial as a means of promoting immune regulation in kidney transplant recipients with the objective of safely minimizing maintenance immunosuppression (clinicaltrials.gov: NCT02085629).
With the objective of discovering novel markers of human Mregs, mouse monoclonal antibodies (mAb) were raised against human Mregs. In this brief report, we identify dehydrogenase/reductase 9 (DHRS9) as the antigen recognized by one such Mreg-reactive mAb (ASOT1). Within a panel of differently polarised monocyte-derived macrophages, expression of DHRS9 mRNA and protein was essentially restricted to Mregs. Lipopolysaccharide (LPS) stimulation did not extinguish DHRS9 expression by Mregs; therefore, DHRS9 behaves as a relatively specific and stable marker of in vitro generated human Mregs.
MATERIALS AND METHODS

Generation of Human Monocyte-Derived Macrophages
Mregs and IFN-γ-Mφ were generated according to previously described methods 2 from peripheral blood leucocytes obtained as a by-product of thrombocyte collection from healthy donors. Briefly, CD14 + monocytes were isolated from Ficoll-prepared peripheral blood mononuclear cells (PBMC) by positive-selection with anti-CD14 microbeads (Miltenyi, Bergisch-Gladbach) and were then plated in 6-well Cell+ plates (Sarstedt, Nümbrecht) at 10 5 cells/cm 2 in RPMI-1640 (Lonza, Cologne) supplemented with 10% heat-inactivated human AB serum (Lonza), 2 mM Glutamax (Invitrogen, Karlsruhe), 100 U/mL penicillin (Lonza), 100 μg/mL streptomycin(Lonza), andrhM-CSF(R&D Systems, WiesbadenNordenstadt) at 5 ng/mL carried on 0.1% human albumin (CSL-Behring, Hattersheim-am-Main). On day 6 of culture, cells were stimulated for a further 18 to 24 hours with 25 ng/mL rhIFN-γ (Chemicon, Billerica, MA). IFN-γ-stimulated macrophages (IFN-γ-Mφ) were generated by cultivating CD14 + monocytes under identical conditions to Mregs except that human serum was replaced with 10% heatinactivated fetal calf serum (Biochrom, Berlin). Macrophages (Mφ) in other defined states of polarization 5 were generated from positively isolated CD14 + monocytes according to protocols adapted from the literature 6-9 and previously published methods 2 (see Table 1 for a summary of culture conditions). The tolerogenic monocyte-derived therapeutic cell products 10 shown in Figures 2F and G were prepared during The ONE Study workshop from CD14 + monocytes isolated by CliniMACS from leucapheresis products from 6 healthy, male donors (Table 1) .
Flow Cytometry
Cells were stained for flow cytometry following standardized protocols, in brief, surface staining was performed at 4°C in staining buffer (DPBS/1% BSA/0.02% NaN 3 /10% FcRblock, Miltenyi) for 60 minutes using the directly-conjugated antibodies listed in Table 2 . In all cases, saturating antibody concentrations were used and dead cells were excluded by 7-AAD staining (BD Biosciences). Data were captured with a Calibur cytometer (BD Biosciences) and analyzed with FlowJo (Tree Star Inc).
Western Blotting, Immunoprecipitation, and Protein Sequencing
Gel electrophoresis and immunoblotting were performed per conventional methods. Protein A/G sepharose (SigmaAldrich) was used to immunoprecipitate the antigen of ASOT1, which was then sequenced by MALDI-MS (Proteome Factory, Berlin).
Immunocytochemistry and Histology
Cytological specimens were stained as previously described elsewhere. 11 Tissue sections were stained with anti-DHRS9 mAb (clone 3C6) following established protocols and were then evaluated by a qualified clinical histopathologist.
PCR
RNAwas isolated using RNeasy Plus kits (Qiagen). SuperScript-III (Invitrogen) was used for reverse-transcription reactions. qPCR was performed with a LightCycler real-time PCR system using the FastStart DNA Master SYBR Green I kit (Roche Diagnostics). DHRS9 primer sequences and cycling conditions are presented in Table 3 . DHRS9 signals were normalised against GAPDH mRNA expression. ALDH1A1, ALDH1A2, BCO1, BCO2, and CD1C were amplified using predesigned primer pairs (QuantiTect, Qiagen) per the manufacturer's recommendations. PCR specificity was confirmed sequencing of amplicons (MWG Biotech).
RESULTS
DHRS9 Expression Uniquely Identifies Mregs Amongst Comparator Macrophages
Although the CD14 −/low CD16 −/low TLR2 − and CD163
−/low cell-surface phenotype distinguished human Mregs from a variety of differently polarised monocyte-derived macrophages, this specification relies upon the absence of marker expression in Mregs (Figure 1 ). To identify positive markers of Mregs, a FIGURE 2. DHRS9 expression distinguishes human Mregs from monocyte-derived macrophages and DCs. A, In immunocytochemistry, the ASOT1 mAb recognized an antigen expressed by Mregs, but not comparator macrophages. B, An antigen of~35 kDa was specifically immunoprecipitated by ASOT1 and was subsequently identified by MALDI-MS as DHRS9. C, Strong DHRS9 mRNA expression was detected in Mregs, but not comparator macrophage types (n = 6; mean ± SD). D, ASOT1 precipitated an antigen which was also recognized by an anti-DHRS9 rabbit pAb (generated in-house) and a mouse mAb (clone 3C6, Abnova), confirming that ASOT1 recognizes DHRS9. E, Immunoblotting with our custom-made rabbit anti-DHRS9 pAb demonstrated that DHRS9 protein expression distinguishes Mregs from comparator macrophages. F, DHRS9 mRNA expression distinguished human Mregs from a panel of tolerogenic monocyte-derived therapeutic cell products. G, DHRS9 protein was detected in human Mregs but not other tolerogenic monocyte-derived therapeutic cell products using a commercial rabbit anti-DHRS9 pAb (ab98155, Abcam).
series of mAb were generated by vaccinating mice with human Mreg lysates. Screening these mAb by immunocytochemistry identified a mAb clone (ASOT1) that reacted strongly with Mregs, but not other monocyte-derived macrophages (Mφ), including resting Mφ, LPS + IFNγ-stimulated Mφ and IL-4-stimulated Mφ (Figure 2A) . By immunoprecipitation and MALDI-MS sequencing of its antigen, ASOT1 was shown to recognize DHRS9, a little-studied retinol dehydrogenase of the short-chain dehydrogenase/reductase (SDR) family of NAD(P)(H)-dependent oxidoreductases [12] [13] [14] ( Figure 2B ). Quantitative PCR confirmed that high-level expression of DHRS9 mRNA expression was restricted to Mregs within the panel of comparator macrophages ( Figure 2C) . A rabbit polyclonal antibody (pAb) generated in-house against a synthetic peptide (CTDPENVKRTAQWVKNQVGEKG) corresponding to an N-terminal epitope of DHRS9 reacted against a protein of 35 kDa immunoprecipitated by ASOT1 ( Figure 2D ). Since a commercially-available mAb (clone 3C6, Abnova) against DHRS9 also reacted with the same immunoprecipitated protein, it was concluded that both ASOT1 and our custommade rabbit pAb recognized DHRS9. Using our custommade rabbit pAb for immunoblotting, DHRS9 protein expression was shown to be unique to Mregs within a panel of comparator human macrophages ( Figure 2E ). DHRS9 expression was not diminished after stimulation of Mregs with 100 ng/mL LPS for 24 hours (Figures 2C and E) . To ascertain whether DHRS9 expression is a unique property of Mregs or a common characteristic of tolerogenic monocytederived cells, DHRS9 gene and protein expression was examined in samples obtained from The ONE Study Workshop on 'Tolerogenic Monocyte-derived Antigen Presenting Cells.' DHRS9 mRNA expression was significantly higher in Mregs than immature monocyte-derived dendritic cells (mo-DC), tolerogenic DC (Tol-DC), 15 Rapamycin-treated DC (Rapa-DC), 16, 17 IL-10 conditioned DC (DC-10) 18-20 or PGE 2 -induced myeloid-derived suppressor cell 21, 22 ( Figure 2F ). Likewise, at the protein level, DHRS9 expression was greater in Mregs than any of these comparator monocyte-derived cells ( Figure 2G ).
Factors Affecting DHRS9 Expression in Human Macrophages
DHRS9 expression increased steadily throughout the transition of monocytes to Mregs in culture and was further upregulated by IFN-γ stimulation on day 6 ( Figure 3A) . Treatment of resting macrophages with IL-4, plate-bound Ig, dexamethasone, IFN-γ or LPS + IFN-γ did not induce DHRS9 expression to the same level as Mregs ( Figure 2C&E ). Reanalyzing publicly available microarray data 23 revealed an induction of DHRS9 in glucocorticoid (GC)-stimulated Mφ and IFN-γ-stimulated Mφ, but no significant upregulation under 26 other treatment conditions, which are meant to encompass all known states of human monocytederived macrophage polarisation ( Figure 3B ). By contrast, 14 treatment conditions led to more than twofold downregulation of DHRS9 expression. Notably, GC-and IFN-γ-induced DHRS9 mRNA expression was weak compared with DHRS9 expression in Mregs at the mRNA ( Figure 2C ) and protein level ( Figure 2E ). To characterise DHRS9 expression by Mregs at the single-cell level, a flow cytometry method was developed for detecting DHRS9 expression using mAb 3C6 ( Figure 3C ). DHRS9 signal was continuously distributed in Mreg populations, indicating that expression was not restricted to a subset of cells within Mreg cultures ( Figure 3D ). 
DHRS9 expression was greater in Mregs than in either resting
Mφ or IFNγ-stimulated Mφ. Consistent with results from qPCR and microarray analyses, a very low-level of DHRS9 expression was observed in IFNγ-stimulated Mφ.
Human Mregs Express Enzymes Involved in Retinoid Metabolism
The SDR family of retinol dehydrogenases is responsible for conversion of retinol to retinal, which is further metabolised to retinoic acid (RA) by retinal dehydrogenases 14, 24 ( Figure 4A ): expression of ALDH1A1 and ALDH1A2 mRNAwas detectable in Mregs ( Figure 4B ). Retinol is liberated from β-carotene through the action of beta-carotene monooxygenases: expression of BCO2, but not BCO1, was also detected in Mregs ( Figure 4B ). Accordingly, in principle, Mregs express the necessary apparatus to convert retinol and β-carotene to RA. CD1D mRNA expression, which is upregulated by RA through RARα activation 25 was also detected in Mregs.
DHRS9 + Macrophages Are Naturally Present in Human Spleen
Methods for producing human Mregs as a cell-based therapy have been optimized for generating a phenotypically homogeneous and stable population of cells. By contrast, macrophage subsets isolated from tissues tend to be much more heterogeneous. For this reason, in vitro derived human Mregs must be regarded as an artificial cell population; nevertheless, it may be interesting and informative to ask what naturally occurring macrophage subsets are most like in vitro derived Mregs. To ascertain whether DHRS9-expressing macrophages normally exist in tissues, an immunohistochemical staining procedure for fixed specimens was established using mAb 3C6. Soref and colleagues previously reported DHRS9 expression by stratified squamous epithelium of human skin, which was confirmed using our staining method and reagents (data not shown). In earlier work, our group tracked ex vivo generated, radio-labelled allogeneic human Mregs after intravenous administration to a prospective kidney transplant recipient. These studies showed Mregs trafficked in blood through the lung to accumulate in spleen, liver, and bone marrow. 3 Therefore, human spleen sections were stained for DHRS9, revealing a minor population of DHRS9-expressing cells with typical macrophage morphology that appeared to be most prevalent in the subcapsular red pulp ( Figure 5 ). Although it is not possible to conclude that these splenic red pulp macrophages are a physiological counterpart of the in vitro derived human Mreg, the existence of a naturally-occurring DHRS9 + macrophage population suggests that DHRS9 expression by ex vivo generated Mregs is not purely an artefact of cell culture.
Dhrs9 Expression Is Not Upregulated in Mouse Mregs
To ascertain whether Dhrs9 expression could also be used as a marker of mouse Mregs, a previously published microarray data set was reinterrogated. 26 This data set comprised triplicate whole-genome gene-expression profiles from CD11b + Ly6C + Ly6G − bone marrow monocytes, monocyte-derived Mregs, monocyte-derived DC, and 8 other differently treated macrophage populations from C57BL/6 mice ( Figure 6 ). Dhrs9 expression was not upregulated in Mregs or in any other comparator population. Moreover, no other SDRfamily member was selectively upregulated in Mregs, nor any comparator macrophage type. Accordingly, Dhrs9 expression is not useful for distinguishing mouse Mregs from other monocyte-derived cell types. 27 
DISCUSSION
Here, we identify DHRS9 expression as a relatively specific and stable marker of in vitro generated human Mregs, which could be detected by qPCR, immunoblotting, immunohistochemistry and flow cytometry. Within the panel of comparator monocyte-derived macrophages used for this study, DHRS9 expression was principally restricted to Mregs. DHRS9 expression remained stable after LPS stimulation, which shows that certain aspects of the Mreg phenotype are refractory to repolarising signals. Hence, DHRS9 expression appears to be a unique and relatively stable characteristic of human Mregs as a "cell type." 28, 29 As yet, the conditions leading to DHRS9 expression in human Mregs are not fully defined, but GC and IFN-γ appear to enhance DHRS9 expression to some degree. We hypothesize that presently undefined components of serum influence the in vitro development of Mregs from monocytes. In future experiments, assaying DHRS9 expression should facilitate screening of serum-derived factors for Mreg-inducing orsuppressing activity. The functional implications of DHRS9 expression by human Mreg are not clear. Although Mregs express the necessary retinoid metabolising enzymes, we cannot directly infer that Mregs generate RA. Nevertheless, it is well-known that certain tissue-resident macrophage populations responsible for maintaining tissue homeostasis and preventing constitutive inflammation, such as those in the gut, suppress T cell reactions and induce regulatory T cells through production of RA. 30 We speculate that ex vivo generated human Mregs may act through similar pathways when administered to patients.
In conclusion, DHRS9 is a relatively stable and specific marker of human Mreg. The ability to positively identify DHRS9-expressing macrophages as Mregs should greatly facilitate future in vitro studies with these cells and may be useful in searching for a naturally occurring counterpart.
